Oragenics Stock Price, News & Analysis

Oragenics, Inc. (NYSE American: OGEN) has appointed Janet Huffman as Chief Financial Officer, effective March 7, 2023. With over 12 years of experience in financial leadership in healthcare, Huffman's expertise in capital raising and M&A will be crucial for Oragenics' development plans. She previously served as CFO of TRxADE HEALTH and was integral in the merger of Banyan Pediatric Care Centers. Huffman aims to enhance stakeholder value through strategic financial management. Oragenics focuses on combating infectious diseases, particularly with its intranasal COVID-19 vaccine candidate, NT-CoV2-1, leveraging research from the NIH.

Oragenics, Inc. (AMEX: OGEN) has entered an exclusive global licensing agreement with Inspirevax Inc. for the development of NT-CoV2-1, its lead intranasal COVID-19 vaccine candidate, utilizing Inspirevax's BDX301 adjuvant. This partnership establishes a Joint Development Committee to oversee collaborative efforts. Oragenics will be responsible for milestone and royalty payments, with potential for future intranasal vaccine developments. The agreement aims to address unmet medical needs. In December 2022, Oragenics reported no toxicity from prior studies, suggesting a favorable safety profile for NT-CoV2-1.

Oragenics, Inc. (NYSE American: OGEN) announced that it has regained compliance with NYSE American’s continued listing standards as of February 1, 2023. The company received formal notice from NYSE American confirming that it resolved a prior deficiency related to its low stock price. The compliance indicator will no longer appear, and Oragenics is removed from the noncompliant issuers list. CEO Kimberly Murphy expressed satisfaction with the swift resolution and emphasized ongoing research and development efforts.

Oragenics, Inc. (NYSE American: OGEN) announced a 1-for-60 reverse stock split approved by its Board on December 22, 2022. The split aims to help the Company meet NYSE American's continued listing standards by increasing the market price of its shares, reducing outstanding shares from approximately 117.6 million to around 1.9 million. The split will take effect after market close on January 20, 2023, with trading of adjusted shares beginning on January 23, 2023.

Oragenics, Inc. (NYSE American: OGEN) announced findings from its GLP toxicology study of the NT-CoV2-1 intranasal vaccine candidate, reporting no toxicity signals or adverse events. The study supports the company's plan to file for regulatory approval for a Phase 1 clinical study. With no toxicity observed, the vaccine demonstrates a favorable safety and immunogenicity profile. Oragenics aims to address the unmet need for intranasal COVID-19 vaccines, with positive preclinical data indicating strong immune responses against various SARS-CoV-2 variants.

Oragenics, Inc. (AMEX:OGEN) has received a compliance notice from NYSE American, indicating that its stock price has been low for an extended period. The company must improve its stock price or undertake a reverse stock split by June 19, 2023, to regain compliance. The notice does not lead to immediate delisting and stocks will continue trading with a designation of 'BC'. Oragenics remains dedicated to developing its intranasal COVID-19 vaccine and lantibiotics, although the notice may impact future financing efforts.

On December 16, 2022, Oragenics, Inc. (AMEX: OGEN) announced the appointment of Charles Pope as Chairman of the Board, succeeding Dr. Frederick W. Telling. Dr. Telling will remain on the Board as an independent director. Mr. Pope expressed gratitude for Dr. Telling's long service and looks forward to continuing the company's advancement in developing its product candidates, including an intranasal vaccine for COVID-19. Oragenics focuses on combating infectious diseases and is working on new antibiotic solutions.

Oragenics, Inc. (NYSE American: OGEN) is participating in the 2022 BioFlorida Annual Conference from November 2-4 in Miami. The company's President and CEO, Kim Murphy, will speak on a panel titled “BioTrends: Learning from the Pandemic: The Fight Against Infectious Diseases” on November 3 at 2:05 p.m. Eastern Time, held at the Hyatt Regency Miami. Murphy will also engage in one-on-one meetings with investors. Oragenics is focused on developing therapies for infectious diseases, including an intranasal COVID-19 vaccine candidate.

Oragenics, Inc. (NYSE American: OGEN) announced its plans for NT-CoV2-1, an intranasal COVID-19 vaccine, which aims to enhance mucosal immunity. The company is progressing into human clinical trials in early 2023 after favorable results from preclinical studies, including a pivotal toxicology study expected to conclude this year. With advantages like easier administration and greater storage efficiency, Oragenics anticipates NT-CoV2-1 will be pivotal in combating COVID-19 variants. The company plans to submit a Clinical Trial Application to Health Canada following the toxicology report.